ImmuCell reports record sales in first quarter of 2025

PORTLAND, Maine - ImmuCell Corporation (NASDAQ:ICCC), a small-cap biotech company valued at $42.85 million specializing in health and productivity products for cattle, announced a significant increase in sales for the first quarter of 2025. According to InvestingPro data, the company maintains strong financial health with a current ratio of 3.41, indicating robust liquidity to meet short-term obligations. The unaudited sales results revealed a record-setting quarter with $8.1 million in revenue, marking an 11% increase over the same period in 2024.

The company, known for its First Defense® product line and the development of Re-Tain®, a novel treatment for subclinical mastitis in dairy cows, has been experiencing a steady growth in sales. Over the six-month period ending March 31, 2025, ImmuCell saw a 28% increase in sales, reaching $15.8 million, while the twelve-month period showed an identical percentage increase, culminating in $27.3 million in sales. This growth is reflected in the stock's impressive 47% price return over the past six months, though InvestingPro analysis indicates the stock is trading at a relatively high EBITDA multiple of 39.5x.

ImmuCell's President and CEO, Michael F. Brigham, commented on the results, highlighting the reduction of order backlogs and improvements in production output and sales over the past six months. The company's sales for the first quarter of 2025 were at approximately 108% of its estimated full capacity of $30 million per year, a target set during 2023 and 2024 as capital investments were made to expand production capacity.

Despite the positive sales figures, Brigham noted that the controlled launch of their investigational product Re-Tain® is not expected to generate significant revenue or profit at this stage. It is intended to test market acceptance and gather product performance data.

The company plans to host a conference call on Thursday, May 15, 2025, to discuss the unaudited financial results in detail. Investors can access the call by dialing in at the specified numbers provided. For deeper insights into ImmuCell's financial health, valuation metrics, and growth prospects, investors can access the comprehensive Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US stocks with detailed analysis and actionable intelligence.

This report is based on a press release statement from ImmuCell Corporation. The forward-looking statements within the release are subject to various risks and uncertainties, including those related to product development, regulatory approvals, market acceptance, and production capacity. ImmuCell has made no commitment to update any forward-looking statements as new information or future developments occur.

In other recent news, ImmuCell Corporation reported strong financial performance for the fourth quarter of 2024, with revenue reaching $7.8 million, marking a 52% increase from the previous year. The company also saw a significant improvement in gross margin, which rose by 125% compared to the same period in 2023. Despite these positive sales figures, the earnings per share (EPS) stood at $0.06, with no specific forecast provided for comparison. ImmuCell's recent strategic move includes the appointment of Timothy C. Fiori as Chief Financial Officer, aiming to enhance its financial systems and operational efficiency. The company raised $4.4 million through an at-the-market offering, bolstering its cash position to $3.8 million by the end of 2024. Analysts have noted the company's focus on innovative animal health products, which has contributed to its robust performance. ImmuCell is awaiting FDA approval for its RETAIN product, which is expected to impact the dairy market significantly. The company is also exploring strategic options to support its product launch and expansion plans.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.